POPESCU IULIAN PhD,MD, Clinical Department of Radio-Biology at the Fundeni
Clinical Institute in Bucharest
e-mail popdociul @yahoo.com
Dr.
ALINA HALPERN PhD, SF.ŞTEFAN Hospital Bucharest
It
is well recognized that lung localization of the cancer is one with
the weakest therapeutic results, with all scientific conquests as
concerns the therapies obtained from 1950 until today. Surviving more
than 5 years is below 15%, compared to results from other
localizations (99% in prostate cancer, 86% in breast cancer, 66% for
colon cancer, 30% in ENT sphere cancer). In lung cancer encouraging
results have been obtained in the possibility of increasing the
survival time without relapse (disease free survival), but not also
concerning the overall survival. The main task in the treatment of
lung cancer remains the prolongation of overall survival and